or Try an Advanced Search...

    Technical Analysis for ATRA - Atara Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.66 -4.44% -0.03
    ATRA closed down 4.44 percent on Friday, April 19, 2024, on 87 percent of normal volume.
    Earnings due: May 6
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ATRA trend table...
    Date Alert Name Type % Chg
    Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    50 DMA Resistance Bearish -4.44%
    Fell Below 20 DMA Bearish -4.44%
    Bollinger Band Squeeze Range Contraction -4.44%
    Crossed Above 20 DMA Bullish -7.54%
    Bollinger Band Squeeze Range Contraction -7.54%
    20 DMA Resistance Bearish -3.02%
    Older End-of-Day Signals for ATRA ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support about 18 hours ago
    20 DMA Resistance about 18 hours ago
    Fell Below Lower Bollinger Band about 18 hours ago
    Down 5% about 21 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ATRA Chart by TradingView
    Basic chart:

    Profile

    Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease

    Is ATRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 5 Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Mar 28 Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
    Mar 28 Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M
    Mar 28 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
    Feb 29 FDA clears Atara to begin Phase 1 study for lupus nephritis drug
    Feb 29 Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
    Feb 28 Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
    Feb 14 Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma
    Feb 14 Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
    Feb 6 Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
    See more ATRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.015
    52 Week Low 0.1986
    Average Volume 1,874,017
    200-Day Moving Average 1.11
    50-Day Moving Average 0.73
    20-Day Moving Average 0.71
    10-Day Moving Average 0.71
    Average True Range 0.07
    RSI (14) 42.20
    ADX 22.57
    +DI 18.49
    -DI 19.85
    Chandelier Exit (Long, 3 ATRs) 0.63
    Chandelier Exit (Short, 3 ATRs) 0.82
    Upper Bollinger Bands 0.78
    Lower Bollinger Band 0.64
    Percent B (%b) 0.13
    BandWidth 18.79
    MACD Line -0.01
    MACD Signal Line 0.00
    MACD Histogram -0.005
    Fundamentals Value
    Market Cap 67.37 Million
    Num Shares 102 Million
    EPS -2.78
    Price-to-Earnings (P/E) Ratio -0.24
    Price-to-Sales 18.35
    Price-to-Book 1.97
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.76
    Resistance 3 (R3) 0.77 0.74 0.75
    Resistance 2 (R2) 0.74 0.71 0.73 0.74
    Resistance 1 (R1) 0.70 0.70 0.68 0.69 0.73
    Pivot Point 0.67 0.67 0.66 0.67 0.67
    Support 1 (S1) 0.63 0.64 0.62 0.63 0.59
    Support 2 (S2) 0.60 0.63 0.60 0.58
    Support 3 (S3) 0.56 0.60 0.58
    Support 4 (S4) 0.56